Singapore markets closed

ALGS Dec 2024 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 09:39AM EDT. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike2.50
Expiry date2024-12-20
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume2
Open interest12
  • Zacks

    Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

    Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.

  • Zacks

    AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

    AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.

  • GlobeNewswire

    Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

    SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The clinical poster presentations highlight the continued potent an